NCT04356729View on ClinicalTrials.gov

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8Stage IV MelanomaUnresectable Stage III Cutaneous MelanomaUnresectable Stage IV Cutaneous Melanoma
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.

DRUG

Bevacizumab

Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.

Trial Locations (3)

02115

Dana Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Elizabeth Buchbinder, MD

OTHER

NCT04356729 - A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter